Crescita Therapeutics Inc. (TSE:CTX – Get Free Report) was up 1.8% during trading on Monday . The company traded as high as C$0.58 and last traded at C$0.58. Approximately 3,525 shares traded hands during mid-day trading, a decline of 40% from the average daily volume of 5,882 shares. The stock had previously closed at C$0.57.
Crescita Therapeutics Stock Up 1.8 %
The company has a debt-to-equity ratio of 6.02, a current ratio of 3.37 and a quick ratio of 2.29. The company has a market cap of C$11.24 million, a P/E ratio of -3.87 and a beta of 1.69. The stock has a 50-day moving average of C$0.58 and a 200 day moving average of C$0.59.
Insider Buying and Selling
In other Crescita Therapeutics news, Director Jose Darocha acquired 86,000 shares of Crescita Therapeutics stock in a transaction that occurred on Friday, December 27th. The shares were acquired at an average cost of C$0.60 per share, with a total value of C$51,436.60. 10.87% of the stock is owned by company insiders.
About Crescita Therapeutics
Crescita Therapeutics Inc, a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers (MMPE) and DuraPeel for the development of topicals containing cannabis and hemp.
Read More
- Five stocks we like better than Crescita Therapeutics
- Manufacturing Stocks Investing
- Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Super Micro Computer: Turning Risk Into Reward at the Crossroads
- What Is WallStreetBets and What Stocks Are They Targeting?
- After a Reset Year, Is Moderna Stock Poised for a Comeback?
Receive News & Ratings for Crescita Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescita Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.